Prakt. lékáren. 2013; 9(3): 127-130

Optizorb® technology in acute pain managment

Boris Leštianský1, Lenka Součková2
1 Úrad pre dohľad nad zdravotnou starostlivosťou, Bratislava, SR
2 Oddělení klinických studií, ICRC a FN u sv. Anny, Brno

The new pharmaceutical drug technologies are designed to improve the pharmacokinetic properties of drug agents. In recent years,

newer substances known as „superdisintegrants“ have been developed. These substances are more effective at low concetrations due to

water absorption and faster disintegration of tablets. Newer commercially available non-opioid analgesics used in acute outpatient pain

management are focused on fasting onset of effective analgesia and rapid control of pain.

Keywords: acute pain, non-opioid analgesic agents, paracetamol, Optizorb® techn ology

Published: July 15, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Leštianský B, Součková L. Optizorb® technology in acute pain managment. Praktické lékárenství. 2013;9(3):127-130.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hakl M, Leštianský B, Hřib R. Pozice nimesulidu ve strategii léčby bolesti. Medicína po promoci 2009; 10(2): 107-110, ISSN 1212-9445.
    2. Ševčík P, Málek J, et al. Doporučené postupy pro léčbu akutní pooperační bolesti, 2008, dostupné na: http://www.csarim.cz/Public/csarim/doc/postupy/Guid_CSARIM_defin080609.pdf.
    3. Bertolini A. Paracetamol: New vistas of an old drug. CNS Drug Review, 2006; 12: 250-275. Go to original source... Go to PubMed...
    4. Schug S. Update on the role of non-opioids for postoperative pain treatment. Best pract., Res. Clin. Anaesth., 2007; 21(1): 15-30. Go to original source... Go to PubMed...
    5. Olson J. Acute pain management - an update, Ann. Queenstown update in Anaesthesia, 2011: 57-63.
    6. Fast release paracetamol tablets, patent WO2007118063A1.
    7. Schiermeier S, Schmidt PC. Fast dispersible ibuprofen tablets. Eur. J. Pharm. Sci., 2002; 15(3): 295-305. Go to original source... Go to PubMed...
    8. Wilson C. Disintegrationand Gastric Emptying of a New Fast - Dissolving Formulation of Paracetamol (Panadol Novum) versus Standard Paracetamol Tablets, Abstract PH 217, IASP, 12th World Congresson Pain, Glasgow 2008: 17-22. Go to original source...
    9. Wilson CG, Clarke CP, et al. Comparison of a novel fast-dissolving acetaminophen tablet formulation (FD-APAP) and standard acetaminophen tablets using gamma scintigraphy and pharmacokinetic studies. Drug Development and Industrial Pharmacy 2011; 37(7): 747-753. Go to original source... Go to PubMed...
    10. Dongzhou JL, et al. Pharmacokinetic and bioequivalence study evaluating a new paracetamol/caffeine formulation in healthy human volunteers, J. Bioequival. Bioavail., 2011; 3(11): 251-257.
    11. Nitesh Sh, Telange D. Determination of the concentration blends of superdisintegrant for fast disintegrating tablets, IJPSR, 2011; 2(11): 2828-2835.

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.